Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Vilastobart · XTX-101

Monoclonal antibody · Antagonist of CTLA-4 · developed by Xilio Development

Phase 1/2 Most advanced trial (none active)
XLO Developer
1 Registered trials

What is Vilastobart?

Vilastobart is a humanized, Fc-engineered monoclonal antibody with masked antigen-binding regions that are activated by proteases upregulated in the tumor microenvironment. It binds CTLA-4 on T-cells, blocking its inhibition of T-cell activation, and is being studied in advanced solid tumors, including in combination with atezolizumab.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
XTX-101
Drug type
Monoclonal antibody
Targets
CTLA-4
Mechanism
Antagonist of CTLA-4
Pathways
T-cell activation, cytotoxic T-lymphocyte-mediated antitumor immune response
Therapy area
Oncology
Developer
Xilio Development, Inc. (XLO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
8FUE2D4G82

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04896697 Phase 1/2 Advanced Solid Tumor Completed XLO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumor

Other drugs acting on CTLA4

More from Xilio Development

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the XLO page.

Follow XLO, the company behind Vilastobart

See XLO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XLO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.